One million haemopoietic stem-cell transplants: a retrospective observational study

The Lancet Haematology

Volumn 2, Issue 3, 2015, Pages e91-e100

  Gratwohl, Alois ^a   Pasquini, Marcelo C ^b   Aljurf, Mahmoud ^c   Atsuta, Yoshiko ^d   Baldomero, Helen ^a   Foeken, Lydia ^e   Gratwohl, Michael ^f   Bouzas, Luis Fernando ^g   Confer, Dennis ^h   Frauendorfer, Karl ^f   Gluckman, Eliane ⁱ   Greinix, Hildegard ^j   Horowitz, Mary ^b   Iida, Minako ^k   Lipton, Jeff ^l   Madrigal, Alejandro ^m   Mohty, Mohamad ⁿ   Noel, Luc ^o   Novitzky, Nicolas ^p   Nunez, José ^o   Oudshoorn, Machteld ^e   Passweg, Jakob ^a   van Rood, Jon ^q   Szer, Jeff ^r   Blume, Karl ^s   Appelbaum, Frederic R ^t   Kodera, Yoshihisa ^k   Niederwieser, Dietger ^u   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d JAPANESE DATA CENTER FOR HEMATOPOIETIC CELL TRANSPLANTATION   (Japan)

^e Europdonor Foundation   (Netherlands)

^f UNIVERSITY OF ST GALLEN   (Switzerland)

^g INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^h NATIONAL MARROW DONOR PROGRAM   (United States)

ⁱ EUROCORD   (France)

^j UNIVERSITY OF VIENNA   (Austria)

^k AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l PRINCESS MARGARET HOSPITAL   (Canada)

^m ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁿ HÔPITAL SAINT ANTOINE   (France)

^o WORLD HEALTH ORGANIZATION   (Switzerland)

^p African Blood and Marrow Transplant Group   (South Africa)

^q Bone Marrow Donors Worldwide   (Netherlands)

^r ROYAL MELBOURNE HOSPITAL   (Australia)

^s STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t Fred Hutchinson Cancer Research Center   (United States)

^u UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CORD BLOOD STEM CELL TRANSPLANTATION; ECONOMIC EVALUATION; ELECTRONIC MEDICAL RECORD; GROSS NATIONAL INCOME; HEALTH SURVEY; HEMOGLOBINOPATHY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT HISTORY OF BONE MARROW TRANSPLANTATION; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; VALIDATION STUDY; GLOBAL HEALTH; HEMATOPOIETIC STEM CELL TRANSPLANTATION; REGISTER;

DATA COLLECTION; GLOBAL HEALTH; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84930322558     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00028-9     Document Type: Article

References (46)

1. Warwick, RM, Chapman, J, Pruett, TL, Wang, H, Globally consistent coding systems for medical products of human origin. Bull World Health Organ, 91, 2013, 314 314A.
2. Linden, PK, History of solid organ transplantation and organ donation. Crit Care Clin 25 (2009), 165–184.
3. Sleeboom-Faulkner, M, Experimental treatments: regulating stem-cell therapies worldwide. Nature, 495, 2013, 47.
4. Efrat, A, The politics of combating the organ trade: lessons from the Israeli and Pakistani experience. Am J Transplant 13 (2013), 1650–1654.
5. World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation 90 (2010), 229–233.
6. Aljurf, M, Rizzo, JD, Mohty, M, et al. Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. Bone Marrow Transplant 49 (2014), 1016–1021.
7. Epstein, JS, Best practices in regulation of blood and blood products. Biologicals 40 (2012), 200–204.
8. Stafinski, T, McCabe, CJ, Menon, D, Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 28 (2010), 113–142.
9. Tunis, SR, Pearson, SD, Coverage options for promising technologies: Medicare's ‘coverage with evidence development’. Health Aff (Millwood) 25 (2006), 1218–1230.
10. Copelan, EA, Hematopoietic stem-cell transplantation. N Engl J Med 354 (2006), 1813–1826.
11. Ljungman, P, Bregni, M, Brune, M, et al., the European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 45 (2010), 219–234.
12. Pasquini, MC, Wang, Z, Horowitz, MM, Gale, RP, 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl 2010 (2010), 87–105.
13. Higgs, DR, A new dawn for stem-cell therapy. N Engl J Med 358 (2008), 964–966.
14. Martin, I, Baldomero, H, Bocelli-Tyndall, C, et al. The survey on cellular and engineered tissue therapies in Europe in 2011. Tissue Eng Part A 20 (2014), 842–853.
15. Hirt, MN, Hansen, A, Eschenhagen, T, Cardiac tissue engineering: state of the art. Circ Res 114 (2014), 354–367.
16. Fulco, I, Miot, S, Haug, M, et al. Engineered autologous cartilage tissue for nasal reconstruction after tumour resection: an observational first-in-human trial. Lancet 384 (2014), 337–346.
17. National Marrow Donor Programme. Media fact sheet: 1 million blood stem cell transplants Worldwide. http://www.wbmt.org/fileadmin/pdf/01_General/One_Million_Transplants_Fact_Sheet_FINAL.pdf (assessed Jan 14, 2015).
18. Osgood, EE, Riddle, MC, Mathews, TJ, Aplastic anemia treated with daily transfusions and intravenous marrow; a case report. Ann Intern Med 13 (1939), 357–367.
19. Thomas, ED, Lochte, HL Jr, Lu, WC, Ferrebee, JW, Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257 (1957), 491–496.
20. Bortin, MM, A compendium of reported human bone marrow transplants. Transplantation 9 (1970), 571–587.
21. Passweg, JR, Baldomero, H, Gratwohl, A, et al., the European Group for Blood and Marrow Transplantation (EBMT). The EBMT activity survey: 1990-2010. Bone Marrow Transplant 47 (2012), 906–923.
22. Hurley, CK, Foeken, L, Horowitz, M, Lindberg, B, McGregor, M, Sacchi, N, the WMDA Accreditation and Regulatory Committees. Standards, regulations and accreditation for registries involved in the worldwide exchange of hematopoietic stem cell donors and products. Bone Marrow Transplant 45 (2010), 819–824.
23. Gratwohl, A, Baldomero, H, Aljurf, M, et al., the Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA 303 (2010), 1617–1624.
24. Thomas, ED, Storb, R, Clift, RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 292 (1975), 895–902.
25. Cheson, BD, Lacerna, L, Leyland-Jones, B, Sarosy, G, Wittes, RE, Autologous bone marrow transplantation. Current status and future directions. Ann Intern Med 110 (1989), 51–65.
26. Schulman, KA, Stadtmauer, EA, Reed, SD, et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Bone Marrow Transplant 31 (2003), 205–210.
27. Vogl, DT, Stadtmauer, EA, High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant 37 (2006), 985–987.
28. Thomas, ED, Buckner, CD, Clift, RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301 (1979), 597–599.
29. Thomas, ED, Marrow transplantation for nonmalignant disorders. N Engl J Med 298 (1978), 963–964.
30. Bortin, MM, Bone marrow transplantation in leukemia using family donors other than HLA-identical siblings: a preliminary report from the International Bone Marrow Transplant Registry. Transplant Proc 19 (1987), 2629–2631.
31. Gooley, TA, Chien, JW, Pergam, SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363 (2010), 2091–2101.
32. Petersdorf, EW, Hansen, JA, Martin, PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345 (2001), 1794–1800.
33. Gluckman, E, Broxmeyer, HA, Auerbach, AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321 (1989), 1174–1178.
34. Oudshoorn, M, van Leeuwen, A, vd Zanden, HG, van Rood, JJ, Bone Marrow Donors Worldwide: a successful exercise in international cooperation. Bone Marrow Transplant 14 (1994), 3–8.
35. Gratwohl, A, Baldomero, H, Gratwohl, M, et al., the Worldwide Network of Blood and Marrow Transplantation (WBMT). Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 98 (2013), 1282–1290.
36. Butler, D, US company comes under fire over patent on umbilical cord cells. Nature, 382, 1996, 99.
37. Gratwohl, A, Brand, R, McGrath, E, et al. the Joint Accreditation Committee (JACIE) of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation, the European Leukemia Net. Use of the quality management system “JACIE” and outcome after hematopoietic stem cell transplantation. Haematologica 99 (2014), 908–915.
38. Lombardini, L, Bosi, A, Grosz, S, et al. Haematopoietic stem cell transplantation: a comparison between the accreditation process performed by competent authorities and JACIE in Italy. Vox Sang 105 (2013), 174–176.
39. Boo, M, van Walraven, SM, Chapman, J, et al., the World Marrow Donor Association. Remuneration of hematopoietic stem cell donors: principles and perspective of the World Marrow Donor Association. Blood 117 (2011), 21–25.
40. Goldman, JM, A special report: bone marrow transplants using volunteer donors–recommendations and requirements for a standardized practice throughout the world–1994 update. The WMDA Executive Committee. Blood 84 (1994), 2833–2839.
41. Gratwohl, A, Schwendener, A, Baldomero, H, et al. Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica 95 (2010), 637–643.
42. Frassoni, F, Labopin, M, Powles, R, et al., the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet 355 (2000), 1393–1398.
43. Sorror, M, Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes. Biol Blood Marrow Transplant 15:suppl (2009), 149–153.
44. Gratwohl, A, The EBMT risk score. Bone Marrow Transplant 47 (2012), 749–756.
45. Cornelissen, JJ, Gratwohl, A, Schlenk, RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 9 (2012), 579–590.
46. Gratwohl, A, Organ donation: stricter management of organ transplants. Nature, 488, 2012, 459.